How accurate is a PSA test? Age and cutoff change the answer

At the same PSA cutoff, one study found that the test caught 75% of cancers in men in their 40s and 90% in men 70 or older. But it also gave more positive results to older men without cancer. The study only included men who went on to have a biopsy, so its numbers don’t describe everyone who gets screened. They do show why “How accurate is PSA?” has no single answer.

The American Cancer Society now recommends regular PSA screening for many men. This article looks at how age and the PSA cutoff change the blood test’s accuracy, and why a high result doesn’t necessarily mean cancer. NCI explains what the test measures.

What does the PSA ROC curve show?

Sensitivity is the share of cancers a test catches. Specificity is the share of people without cancer who test negative. Lower the PSA cutoff, and you usually catch more cancers but get more false positives.

At 4 ng/mL, the test caught 86% of biopsy-detected cancers but correctly gave a negative result to only 33% of men without cancer. Raising the cutoff to 10 ng/mL caught 38% of cancers and correctly cleared 84% of men without cancer. The area under this curve (AUC) was 0.67, where 0.5 is chance and 1.0 is perfect separation.

The curve shows the cutoff tradeoff among men who had a biopsy. Source: Hoffman et al., BMC Family Practice, 2002.

Only 2,620 of more than 40,000 tested men in this study had a biopsy within a year. They were more likely to have a concerning result than men who didn’t have one. So the 33% specificity can’t be used to predict false positives among everyone offered screening. The study also counted any cancer found on biopsy, including cancers that might never cause harm.

How do sensitivity and specificity change with age?

At a fixed cutoff of 4 ng/mL, sensitivity rose with age while specificity fell:

Age at test	Sensitivity	Specificity
40–49	75%	55%
50–59	80%	40%
60–69	84%	32%
70 or older	90%	27%

These figures come from men who had a biopsy in 1995–1998, not from a modern screening program. In the same study, raising the cutoff for men 70 or older from 4 to 6.5 ng/mL improved specificity from 27% to 49%, but sensitivity fell from 90% to 70%. The cutoff changes both sides of the result. These historical thresholds aren’t advice for interpreting your own test. Hoffman et al., Tables 4–5.

Why does PSA rise with age?

The prostate often grows with age, and benign enlargement can raise PSA. So can inflammation or infection. In a Minnesota community study, median PSA was 0.7 ng/mL in men in their 40s and 2.1 in men in their 70s. The chart shows the decades between them.

Median PSA rose across age groups in this Minnesota cohort of White men; the values aren’t cancer cutoffs. Source: Jacobsen et al., Mayo Clinic Proceedings, 2012.

A larger 2025 All of Us study found the same age pattern. Among 13,749 men without a known history of prostate cancer or elevated PSA at enrollment, the 95th percentile rose from 1.81 ng/mL at ages 40–49 to 5.53 at ages 70–79. Those are upper-end values, not the medians shown in the chart.

PSA also changes within one person. In the Minnesota cohort, the median annual change between tests taken two years apart was 4.83%, with much larger changes in some men. That number isn’t a cutoff for a dangerous rise. The AUA/SUO guideline recommends repeating a newly elevated PSA before imaging or biopsy; it reports that 25%–40% return to a normal level on retesting.

What does a positive PSA result mean?

Sensitivity and specificity don’t tell you the chance that your high PSA means cancer. That also depends on how common cancer is among people like you, and whether the study counts any cancer or only cancer likely to cause harm.

In a more recent study of 12,670 Swedish men ages 50–74, a 3 ng/mL cutoff had 74% sensitivity and 90% specificity for clinically significant cancer diagnosed within two years. Per 1,000 men tested, about 26 had a positive PSA and such a diagnosis, 9 had a negative PSA and such a diagnosis, and 95 had a positive PSA without one. Some of those 95 may have had low-risk cancer. These are results from one baseline test, not the accuracy of the full ACS screening pathway. Palsdottir et al., Annals of Internal Medicine, 2026.

A high PSA calls for a follow-up plan, not an automatic biopsy. Age, prior results, family history, and symptoms also shape that plan. For the new screening ages and next steps after an elevated result, see our ACS guideline explainer.